FUSION PROTEIN WITH IMMUNOSUPPRESSIVE ACTIVITY

The present invention provides a compound comprising a fusion polypeptide of formula (I): R1-L-R2-Fc wherein R1, which is at the N-terminal end of the polypeptide, is PD-L2 or a PD1-binding fragment thereof, L is a peptide linker, R2 is CTLA-4 or a CD80/CD86-binding fragment thereof, and Fc, which i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	BESTARD MATAMOROS, Oriol, GRINYÓ BOIRA, Josep Maria, TORRAS AMBROS, Juan
Format:	Patent
Sprache:	eng ; fre ; ger
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention provides a compound comprising a fusion polypeptide of formula (I): R1-L-R2-Fc wherein R1, which is at the N-terminal end of the polypeptide, is PD-L2 or a PD1-binding fragment thereof, L is a peptide linker, R2 is CTLA-4 or a CD80/CD86-binding fragment thereof, and Fc, which is at the C-terminal end of the polypeptide, is an immunoglobulin Fc domain. The present invention also provides a dimer of the compound, a polynucleotide which encodes the polypeptide, a vector comprising the polynucleotide, a host cell which contains the polynucleotide, a composition and a kit comprising the compound. The invention also provides the compound or the dimer for use in therapy, diagnosis and prognosis, in particular for the treatment of autoimmune diseases or transplant rejection.